HK Stock Market Move | DUALITYBIO-B(09606) rose over 4% in early trading, ADAM9-targeted ADC cancer new drug approved for clinical trials in China.

DUALITYBIO-B (09606) rose over 4% in the morning session, as of the time of writing, it is up by 2.42% and is trading at 363.6 Hong Kong dollars with a turnover of 51.05 million Hong Kong dollars. On the news front, on January 19th, Ennogen announced that its independently developed ADAM9 targeted antibody-drug conjugate (ADC) DB-1317 has obtained approval for new drug clinical trials from the drug evaluation center of the National Medical Products Administration (CDE), allowing for its use as a single agent in clinical trials for advanced/metastatic solid tumor patients. It is reported that DB-1317 is a new generation ADC product developed based on Ennogen's proprietary ADC technology platform DITAC, with global rights. Its target ADAM9 is highly expressed in various tumors such as gastric cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, but has low expression levels in normal tissues. Preclinical studies have shown that DB-1317 exhibits significant anti-tumor activity in various tumor models.